-
公开(公告)号：EP3288948B1
公开(公告)日：2019-11-20
申请号：EP16720183.9
申请日：2016-04-29
申请人： Novartis AG
发明人： CHIANELLI, Donatella , LIU, Xiaodong , MOLTENI, Valentina , NELSON, John , ROLAND, Jason , RUCKER, Paul Vincent , TULLY, David Charles
IPC分类号： C07D493/04 , A61K31/4162 , A61P1/16
-
2.发明公开
公开(公告)号：EP2152688A1
公开(公告)日：2010-02-17
申请号：EP08747596.8
申请日：2008-05-02
申请人： IRM LLC , Novartis AG , Li, Xiaolin , Liu, Xiaodong , Molteni, Valentina , Chianelli, Donatella , Loren, Jon , Nabakka, Juliet
发明人： LI, Xiaolin , LIU, Xiaodong , MOLTENI, Valentina , CHIANELLI, Donatella , LOREN, Jon , NABAKKA, Juliet , RAMSEY, Timothy , BREITENSTEIN, Werner
IPC分类号： C07D401/04 , C07D417/14 , A61K31/506 , A61P35/00 , A61P37/00
CPC分类号： C07D401/04 , C07D417/14
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFR and PDGFR kinases.
摘要翻译： 本发明提供了一类新化合物，包含此类化合物的药物组合物以及使用此类化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症，特别是涉及c-kit，PDGFR和PDGFR异常活化的疾病或病症的方法 PDGFR激酶。
-
3.发明公开COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS 有权ZUSAMMENSETZUNGEN UND VERFAHREN ZUR MODULIERUNG VON FARNESOID-X-REZEPTOREN
公开(公告)号：EP3065738A1
公开(公告)日：2016-09-14
申请号：EP14803001.8
申请日：2014-11-04
申请人： NOVARTIS AG
发明人： TULLY, David , CHIANELLI, Donatella , LIU, Xiaodong , MOLTENI, Valentina , NELSON, John , ROLAND, Jason , RUCKER, Paul
IPC分类号： A61K31/4162 , C07D471/04 , C07D491/052
CPC分类号： C07D231/54 , A61K31/416 , A61K31/4162 , A61K31/4439 , A61K31/4745 , C07D471/04 , C07D471/06 , C07D491/052
摘要： a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
摘要翻译： 立体异构体，对映体，其药学上可接受的盐或氨基酸缀合物; 其中变量如本文所定义; 和它们的药物组合物，其可用作法呢甾X受体（FXR）活性的调节剂。
-
4.发明授权DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS 有权DIARYLAMINHALTIGE化合物和组合物及其作为C-KIT受体调节剂
公开(公告)号：EP1928236B1
公开(公告)日：2011-11-23
申请号：EP06815653.8
申请日：2006-09-26
申请人： IRM LLC , Novartis AG
发明人： MOLTENI, Valentina , LI, Xiaolin , CHIANELLI, Donatella , LOREN, Jon , LIU, Yi , KARANEWSKY, Donald, S. , FURET, Pascal , GUAGNANO, Vito , YOU, Shuli , NABAKKA, Juliet , LIU, Xiaodong , PAN, Shifeng
CPC分类号： C07D403/04 , C07D239/42 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/04 , C07D413/12 , C07D417/12 , C07D471/04 , C07D491/10
摘要： Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.
-
公开(公告)号：EP2079729A1
公开(公告)日：2009-07-22
申请号：EP07844851.1
申请日：2007-11-02
申请人： IRM LLC , NOVARTIS AG
发明人： CHIANELLI, Donatella , LI, Xiaolin , LIU, Xiaodong , LOREN, Jon , MOLTENI, Valentina , NABAKKA, Juliet , REVESZ, Laszlo , PEREZ, Lawrence B. , BROOKS, Clinton , WRONA, Wojciech , MANLEY, Paul W. , BREITENSTEIN, Werner
IPC分类号： C07D401/14 , C07D403/12 , C07D405/14 , C07D407/14 , C07D413/14 , C07D417/14 , C07D471/04 , A61K31/506 , A61P33/06 , A61P25/00 , A61P35/00
CPC分类号： C07D401/14 , C07D401/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to beat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases. Formula (I).
摘要翻译： 本发明提供了一类新化合物，包含此类化合物的药物组合物以及使用这些化合物来击败或预防与异常或失调的激酶活性相关的疾病或病症，特别是涉及c-kit，PDGFRα和PDGFRα异常活化的疾病或病症 PDGFRβ激酶。 公式（I）。
-
公开(公告)号：EP2751102B1
公开(公告)日：2019-03-27
申请号：EP12756879.8
申请日：2012-08-28
申请人： Novartis AG
发明人： YEH, Vince , LI, Xiaolin , LIU, Xiaodong , LOREN, Jon , MOLTENI, Valentina , NABAKKA, Juliet , NGUYEN, Bao , PETRASSI, Hank Michael James
IPC分类号： C07D471/04 , A61K31/437 , A61P29/00 , A61P3/00 , A61P17/00 , A61P11/00
-
公开(公告)号：EP3065738B1
公开(公告)日：2018-02-28
申请号：EP14803001.8
申请日：2014-11-04
申请人： NOVARTIS AG
发明人： TULLY, David , CHIANELLI, Donatella , LIU, Xiaodong , MOLTENI, Valentina , NELSON, John , ROLAND, Jason , RUCKER, Paul
IPC分类号： A61K31/4162 , C07D471/04 , C07D491/052 , A61P1/16 , A61P1/18
CPC分类号： C07D231/54 , A61K31/416 , A61K31/4162 , A61K31/4439 , A61K31/4745 , C07D471/04 , C07D471/06 , C07D491/052
摘要： a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
-
8.发明公开DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS 有权DIARYLAMINHALTIGE化合物和组合物及其作为C-KIT受体调节剂
公开(公告)号：EP1928236A2
公开(公告)日：2008-06-11
申请号：EP06815653.8
申请日：2006-09-26
申请人： IRM, LLC , Novartis AG
发明人： MOLTENI, Valentina , LI, Xiaolin , CHIANELLI, Donatella , LOREN, Jon , LIU, Yi , KARANEWSKY, Donald, S. , FURET, Pascal , GUAGNANO, Vito , YOU, Shuli , NABAKKA, Juliet , LIU, Xiaodong , PAN, Shifeng
CPC分类号： C07D403/04 , C07D239/42 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/04 , C07D413/12 , C07D417/12 , C07D471/04 , C07D491/10
摘要： Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.
-
公开(公告)号：EP3630771A1
公开(公告)日：2020-04-08
申请号：EP18734297.7
申请日：2018-05-29
申请人： Novartis AG
发明人： JIRICEK, Jan , LERARIO, Isabelle K. , LIANG, Fang , LIU, Xiaodong , MOLTENI, Valentina , NAGLE, Advait Suresh , NG, Shuyi Pearly , RATNIKOV, Maxim , SMITH, Jeffrey M. , XIE, Yongping
IPC分类号： C07D487/04 , C07D519/00 , A61P33/02 , A61K31/53
-
10.发明公开FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR MODULATING FARNESOID X RECEPTORS 有权融合的三环吡唑衍生物可用于调控法尼酸X受体
公开(公告)号：EP3288948A1
公开(公告)日：2018-03-07
申请号：EP16720183.9
申请日：2016-04-29
申请人： Novartis AG
发明人： CHIANELLI, Donatella , LIU, Xiaodong , MOLTENI, Valentina , NELSON, John , ROLAND, Jason , RUCKER, Paul Vincent , TULLY, David Charles
IPC分类号： C07D493/04 , A61K31/4162 , A61P1/16
摘要： a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.023 秒)
